1.0 2009-07-30 17:59:10 UTC 2026-05-14 16:58:21 UTC T3D3537 Terazosin SmallMolecule Terazosin is an exogenous organic compound with the formula C19H25N5O4 and an average molecular weight of 387.43 g/mol. At room temperature, it exists as a solid. Terazosin belongs to the piperazines, a subclass of diazinanes within the organic compounds. The compound is recorded in 11 sources, including healthcare, pharmaceuticals, and veterinary products as a drug used in benign prostatic hypertrophy; food, food processing, and cookware for food preservation; household cleaning and consumer products such as tobacco smoke filters, cigar cigarettes, non-electric simulated smoking devices, and other smoking requisites; and electrical and electronic equipment including electrodes, television systems, antennas, conductors or conductive bodies characterised by the conductive materials, and electrically stimulated smoking devices. The recorded exposure route is oral. Terazosin acts on seven protein targets. It selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors—specifically the alpha-1A (ADRA1A), alpha-1B (ADRA1B), and alpha-1D (ADRA1D) adrenergic receptors—which results in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alpha-adrenergic blockers phentolamine and phenoxybenzamine, terazosin does not block presynaptic alpha(2)-receptors and therefore does not cause reflex activation of norepinephrine release to produce reflex tachycardia. Additionally, it serves as an inducer of transforming growth factor beta-1 proprotein (TGFB1) and voltage-gated inwardly rectifying potassium channels KCNH2, KCNH6, and KCNH7. Drug Synthetic Toxin Organic Compound Amine Ether Amide Drug Antineoplastic Agent Adrenergic alpha-Antagonist Platelet Aggregation Inhibitor Synthetic Compound Adrenergic alpha-1 Receptor Antagonist Human Neurotoxin 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine Blavin Flumarc Fosfomic Heitrin Hytrin Hytrinex Itrin Terazosin Terazosina Terazosine Terazosinum Urodie Vicard Zayasel C19H25N5O4 387.4329 387.190654313 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine terazosin 70024-40-7 COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1 InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22) VCKUSRYTPJJLNI-UHFFFAOYSA-N Organic compounds Organoheterocyclic compounds Diazinanes Piperazines N-arylpiperazines Alkyl aryl ethers Amino acids and derivatives Aminopyrimidines and derivatives Anisoles Azacyclic compounds Carbonyl compounds Dialkyl ethers Dialkylarylamines Heteroaromatic compounds Hydrocarbon derivatives Imidolactams Organic oxides Organopnictogen compounds Oxacyclic compounds Primary amines Quinazolinamines Tertiary carboxylic acid amides Tetrahydrofurans Alkyl aryl ether Amine Amino acid or derivatives Aminopyrimidine Anisole Aromatic heteropolycyclic compound Azacycle Benzenoid Carbonyl group Carboxamide group Carboxylic acid derivative Dialkyl ether Dialkylarylamine Diazanaphthalene Ether Heteroaromatic compound Hydrocarbon derivative Imidolactam N-arylpiperazine Organic nitrogen compound Organic oxide Organic oxygen compound Organonitrogen compound Organooxygen compound Organopnictogen compound Oxacycle Primary amine Pyrimidine Quinazolinamine Quinazoline Tertiary carboxylic acid amide Tetrahydrofuran Aromatic heteropolycyclic compounds furans piperazines primary amino compound quinazolines Detected and Not Quantified Exogenous Cytoplasm Extracellular Terazosin Drug Metabolism Action Pathway SMP0143582 Terazosin Predicted Metabolism Pathway SMP0174730 Solid Terazosin is a white, crystalline substance, melting_point 273°C solubility 29.7mg/mL logp 1 logp 1.12 ALOGPS logs -2.41 ALOGPS solubility 1.50e+00 g/l ALOGPS logp 1.18 ChemAxon pka_strongest_acidic 19.93 ChemAxon pka_strongest_basic 7.24 ChemAxon iupac 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine ChemAxon average_mass 387.4329 ChemAxon mono_mass 387.190654313 ChemAxon smiles COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1 ChemAxon formula C19H25N5O4 ChemAxon inchi InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22) ChemAxon inchikey VCKUSRYTPJJLNI-UHFFFAOYSA-N ChemAxon polar_surface_area 103.04 ChemAxon refractivity 105.18 ChemAxon polarizability 41.26 ChemAxon rotatable_bond_count 4 ChemAxon acceptor_count 8 ChemAxon donor_count 1 ChemAxon physiological_charge 1 ChemAxon formal_charge 0 ChemAxon Oral. Essentially completely absorbed in man (90% bioavailability). Terazosin selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors, resulting in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alph-adrenergic blockers phenoxybenzamine and phentolamine, terazosin does not block presynaptic alpha(2)-receptors and, hence, does not cause reflex activation of norepinephrine release to produce reflex tachycardia. Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity. Route of Elimination: Approximately 10% of an orally administered dose is excreted as parent drug in the urine and approximately 20% is excreted in the feces. Half Life: 12 hours LD50: 259.3mg/kg (parental-intravenous, Mouse) (A308) No indication of carcinogenicity to humans (not listed by IARC). Terazosin is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin. The long-term effects of terazosin on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin tablets are also indicated for the treatment of hypertension. Terazosin tablets can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. #<HealthEffect::ActiveRecord_Associations_CollectionProxy:0x00007f72224717d8> Asthenia, postural hypotension, dizziness, somnolence, nasal congestion/rhinitis. Should overdosage of Terazosin lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, shock should first be treated with volume expanders. If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. Laboratory data indicate that Terazosin is highly protein bound; therefore, dialysis may not be of benefit. (L1712) DB01162 5401 CHEMBL611 5208 C07127 9445 Terazosin Terazosin 18048412 12461301 Drugs.com: http://www.drugs.com/cons/Terazosin.html RxList: The Internet Drug Index (2009).: http://www.rxlist.com/hytrin-drug.htm RxList: The Internet Drug Index (2009).: http://www.rxlist.com/ BE0000501 Terazosin selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors, resulting in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alph-adrenergic blockers phenoxybenzamine and phentolamine, terazosin does not block presynaptic alpha(2)-receptors and, hence, does not cause reflex activation of norepinephrine release to produce reflex tachycardia. BE0000575 Terazosin selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors, resulting in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alph-adrenergic blockers phenoxybenzamine and phentolamine, terazosin does not block presynaptic alpha(2)-receptors and, hence, does not cause reflex activation of norepinephrine release to produce reflex tachycardia. BE0000715 Terazosin selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors, resulting in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alph-adrenergic blockers phenoxybenzamine and phentolamine, terazosin does not block presynaptic alpha(2)-receptors and, hence, does not cause reflex activation of norepinephrine release to produce reflex tachycardia. BE0000090 BE0000462 BE0000699 BE0000984